Addition of Daratumumab to Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed MM

Source: 2017 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 2-6, 2017; Chicago, Illinois
Daratumumab addition to standard therapy was associated with an ORR of 100% after median follow-up of 10.8 months.
Format: Microsoft PowerPoint (.ppt)
File Size: 530 KB
Released: June 6, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings